Advertisement

Topics

Myogen, Inc. Company Profile

16:39 EDT 20th June 2018 | BioPortfolio

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license or acquire products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies.We have two product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and darusentan for the treatment of resistant hypertension (RHTN). Myogen, in partnership with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders.

Location

7575 W. 103rd Avenue, Suite 102
Westminster
Colorado
80021-5426
United States of America

Contact

Phone: 303-410-6666
Fax: 303-410-6667
Email: IR@myogen.com


News Articles [1 Associated News Articles listed on BioPortfolio]

MyoGen: Leaders of an Anabolic Revolution

GUJARAT, India, May 23, 2018 (GLOBE NEWSWIRE) -- Myogen will make you rethink what the human body is capable of.To be an athlete means to partake on a never-ending quest for self-improvement. ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension

AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study AMB-220, "A P...

Companies [2 Associated Companies listed on BioPortfolio]

Myogen, Inc.

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our adva...

Myogen

Research and development of therapeutics based on signaling pathways in cardiac, hypertrophy, myosin heavy chain research and gene/protein expression profiling using its human cardiac tissue bank.

More Information about "Myogen, Inc." on BioPortfolio

We have published hundreds of Myogen, Inc. news stories on BioPortfolio along with dozens of Myogen, Inc. Clinical Trials and PubMed Articles about Myogen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Myogen, Inc. Companies in our database. You can also find out about relevant Myogen, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...


Corporate Database Quicklinks



Searches Linking to this Company Record